JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 90 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $258,000 | +239.5% | 29,536 | +29.0% | 0.22% | +278.9% |
Q3 2019 | $76,000 | -59.8% | 22,904 | -40.1% | 0.06% | -51.3% |
Q2 2019 | $189,000 | -39.8% | 38,222 | -24.5% | 0.12% | -9.3% |
Q1 2019 | $314,000 | +15.4% | 50,622 | -37.3% | 0.13% | +13.2% |
Q4 2018 | $272,000 | +30.1% | 80,710 | +151.5% | 0.11% | -30.9% |
Q3 2018 | $209,000 | -74.8% | 32,086 | -70.4% | 0.16% | -27.6% |
Q2 2018 | $831,000 | – | 108,517 | – | 0.23% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |